Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

C. Mamolo; J. Harness; H. Tan; A. Menter

doi:10.1111/jdv.12081

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.12081 ◽

2013 ◽

Vol 28 (2) ◽

pp. 192-203 ◽

Cited By ~ 38

Author(s):

C. Mamolo ◽

J. Harness ◽

H. Tan ◽

A. Menter

Keyword(s):

Patient Reported Outcomes ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Controlled Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Patient Reported

Download Full-text

Faculty Opinions recommendation of A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725364136.793541451 ◽

2018 ◽

Author(s):

William Vainchenker ◽

Isabelle Plo

Keyword(s):

Dose Escalation ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Efficacy And Safety ◽

Dose Escalation Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo

Download Full-text

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis

British Journal of Dermatology ◽

10.1111/bjd.13745 ◽

2015 ◽

Vol 173 (3) ◽

pp. 767-776 ◽

Cited By ~ 53

Author(s):

K. Papp ◽

D. Pariser ◽

M. Catlin ◽

G. Wierz ◽

G. Ball ◽

...

Keyword(s):

Dose Escalation ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Efficacy And Safety ◽

Dose Escalation Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo

Download Full-text

OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial

10.1136/annrheumdis-2017-eular.2443 ◽

2017 ◽

Cited By ~ 3

Author(s):

DD Gladman ◽

WFC Rigby ◽

VF Azevedo ◽

F Behrens ◽

R Blanco ◽

...

Keyword(s):

Tumour Necrosis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese pediatric patients with atopic dermatitis: A phase II, randomized, double-blind, vehicle-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.224 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB53

Keyword(s):

Atopic Dermatitis ◽

Phase Ii ◽

Pediatric Patients ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

THU0191 Effects of tofacitinib, an oral janus kinase inhibitor, on patient-reported outcomes in japanese patients with rheumatoid arthritis

10.1136/annrheumdis-2017-eular.1402 ◽

2017 ◽

Author(s):

H Yamanaka ◽

Y Tanaka ◽

T Takeuchi ◽

N Sugiyama ◽

T Hirose ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Patient Reported Outcomes ◽

Kinase Inhibitor ◽

Japanese Patients ◽

Janus Kinase ◽

Janus Kinase Inhibitor ◽

Patient Reported

Download Full-text

Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/j.1468-3083.2011.04394.x ◽

2011 ◽

Vol 27 (1) ◽

pp. 125-128 ◽

Cited By ~ 18

Author(s):

S. Tyring ◽

J. Bagel ◽

C. Lynde ◽

P. Klekotka ◽

E.H.Z. Thompson ◽

...

Keyword(s):

Plaque Psoriasis ◽

Patient Reported Outcomes ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Patient Reported

Download Full-text

Corrigendum to "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.2020;82:823-31

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.07.010 ◽

2021 ◽

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

THU0151 Effects of tofacitinib (CP-690,550), an oral janus kinase inhibitor, or adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis:

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2116 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 206.2-206 ◽

Cited By ~ 4

Author(s):

R.F. van Vollenhoven ◽

G. Wallenstein ◽

E.B. Lee ◽

R. Fleischmann ◽

S.H. Zwillich ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Patient Reported Outcomes ◽

Active Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase 3 ◽

Janus Kinase Inhibitor ◽

Patient Reported

Download Full-text

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: A phase III, randomized, double-blind, vehicle-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.737 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB199

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Japanese Adult ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.12.015 ◽

2020 ◽

Vol 82 (4) ◽

pp. 823-831 ◽

Cited By ~ 19

Author(s):

Hidemi Nakagawa ◽

Osamu Nemoto ◽

Atsuyuki Igarashi ◽

Hidehisa Saeki ◽

Hironobu Kaino ◽

...

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text